stockportfolio.pro
TransMedics Group, Inc. (TMDX)
Healthcare · Medical Devices · NasdaqGM
TransMedics Group, Inc. revenue & earnings — last 8 fiscal years
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.02M | $23.60M | $25.64M | $30.26M | $93.46M | $241.62M | $441.54M | $605.49M |
| Gross profit | $5.73M | $13.86M | $16.64M | $21.16M | $65.27M | $154.09M | $262.08M | $362.81M |
| Net income | $-23.76M | $-33.55M | $-28.75M | $-44.22M | $-36.23M | $-25.03M | $35.46M | $190.29M |
| Net margin | -182.5% | -142.1% | -112.1% | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% |
Source: TransMedics Group, Inc. SEC filings (10-K).
What growth is priced into TMDX stock?
At today's market cap of $2.57B, TransMedics Group, Inc. is priced for free-cash-flow growth of about 7.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $133.59M from the FY ending 2025-12-31). For comparison, revenue 88.2%/yr, computed from its SEC filings. This is a reverse DCF — a translation of the price into a growth assumption you can judge, not a fair value and not advice. Change the assumptions yourself in the interactive view →
Explore 8 years of TransMedics Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track TMDX in your portfolio →
TransMedics Group, Inc. financial history by metric
About TransMedics Group, Inc.
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
TransMedics Group, Inc. — frequently asked questions
What is TransMedics Group, Inc.'s revenue?
TransMedics Group, Inc. (TMDX) reported revenue of $605.49M for fiscal year 2025, up 37.1% from the prior year, according to its SEC filings.
Is TransMedics Group, Inc. profitable?
Yes. TMDX earned net income of $190.29M in fiscal 2025, a net margin of 31.4%.
What is TMDX's P/E ratio?
TransMedics Group, Inc. trades at a price-to-earnings ratio of about 17.0 based on the latest data in our nightly-refreshed cache.
How fast is TransMedics Group, Inc. growing?
TMDX's revenue grew at roughly 88.2% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does TransMedics Group, Inc. have?
As of fiscal year 2025, TMDX carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is TransMedics Group, Inc.'s gross margin?
TMDX's gross margin was 59.9% in fiscal 2025 — gross profit of $362.81M on revenue of $605.49M.
What is TransMedics Group, Inc.'s market cap?
TransMedics Group, Inc. (TMDX) has a market capitalization of about $2.57B, based on the latest data in our nightly-refreshed cache.
When does TransMedics Group, Inc.'s fiscal year end?
TMDX's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
What growth is priced into TMDX stock?
At today's market cap of $2.57B, TransMedics Group, Inc. is priced for free-cash-flow growth of about 7.2% per year for 10 years (assuming a 10% discount rate and 2.5% terminal growth, base FCF $133.59M from the FY ending 2025-12-31). For comparison, revenue 88.2%/yr, computed from its SEC filings.
Where does this data come from?
All figures are computed from TransMedics Group, Inc.'s official SEC filings (10-K and 10-Q), covering 8 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.